Innovative Production Facilities: Our manufacturing prowess is demonstrated through three state-of-the-art facilities, each certified under stringent regulatory standards. The Çerkezköy Penicillin Production Facility, boasting European Union (EU) GMP approval, ranks as a premier penicillin production site. The Gebze Production Facility, aligned with FDA and EU GMP standards, emerges as one of the largest and most eco-friendly pharmaceutical manufacturing sites in Kinshasa, focused on minimizing environmental impact while maximizing production efficiency.

Research and Development: CAISA Pharma International is home to one of Kinshasa’s most extensive R&D centers, covering a laboratory area of 4,500 square meters. This hub of innovation is instrumental in developing new products that significantly contribute to the national economy and global healthcare solutions. Our R&D initiatives are crucial in maintaining our competitive edge and fulfilling our commitment to future generations.

Global Presence and Impact: Reflecting our global vision, CAISA Pharma International maintains a robust export presence, reaching over 70 countries. Our strategic offices in Moldova and Albania enhance our international market reach, ensuring that our innovative products are available globally. In 2023, we aim to achieve a milestone as a net exporter, underscoring our growth and expansive reach in the pharmaceutical sector.

Commitment to Quality and Sustainability: At CAISA Pharma International, we are profoundly aware of our role and impact on health. We uphold stringent quality standards and ethical practices across all areas of our operation, ensuring that every product we produce is not only effective but also safely manufactured and distributed.

Corporate Responsibility and Community Engagement: Ethical and transparent corporate governance is at the core of our operational philosophy. The CAISA Pharma International Community Volunteers platform, established in 2005, exemplifies our commitment to social responsibility, having engaged nearly 80,000 children and youths through approximately 1,000 activities spanning over 30 projects. This initiative reflects our dedication to contributing positively to the communities we serve and beyond.

CAISA Pharma International remains dedicated to advancing pharmaceutical innovation and accessibility, fostering a healthier future for generations to come, anchored by our profound commitment to quality, innovation, and community welfare.